Valuation Panacea Life Sciences Holdings, Inc.

Equities

Delayed OTC Markets Other stock markets 02:32:32 2025-06-13 pm EDT			5-day change	1st Jan Change
0.0366 ^USD	-2.27%		-2.40%	+46.40%

2024	Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2024	Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023
Capitalization ¹	10.13	1.052	2.646
Change	-	-89.62%	151.53%
Enterprise Value (EV) ¹	21.32	18.91	24.18
Change	-	-11.31%	27.88%
P/E ratio	-2.68x	-0.11x	-0.31x
PBR	1.43x	-0.49x	-0.32x
PEG	0.6x	-0x	0x
Capitalization / Revenue	4.92x	0.65x	1.11x
EV / Revenue	10.4x	11.6x	10.1x
EV / EBITDA	-5.08x	-4.82x	-6.31x
EV / EBIT	-3.59x	-3.34x	-4.36x
EV / FCF	41,953,483x	-15,705,445x	-391,028,742x
FCF Yield	0%	-0%	-0%
Dividend per Share ²	-	-	-
Rate of return	-	-	-
EPS ²	-0.2684	-0.6152	-0.4821
Distribution rate	-	-	-
Net sales ¹	2.06	1.627	2.385
EBITDA ¹	-4.2	-3.921	-3.833
EBIT ¹	-5.937	-5.652	-5.546
Net income ¹	-4.782	-9.143	-8.015
Net Debt ¹	11.18	17.85	21.53
Reference price ²	0.7200	0.0703	0.1500
Nbr of stocks (in thousands)	14,074	14,965	17,645
Announcement Date	3/31/22	3/30/23	4/1/24

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
PANACEA LIFE SCIENCES HOLDINGS, INC.	-	-	-	-	777K
ELI LILLY AND COMPANY	37.31x	12.34x	28.08x	0.76%	710B
JOHNSON & JOHNSON	14.6x	4.06x	11.2x	3.44%	367B
NOVO NORDISK A/S	18.65x	6.69x	13.36x	2.7%	335B
ABBVIE INC.	27.73x	6.38x	13.29x	3.53%	328B
ROCHE HOLDING AG	14.31x	3.5x	8.69x	3.78%	258B
NOVARTIS AG	16.89x	4.53x	10.92x	3.37%	230B
ASTRAZENECA PLC	22.55x	4.21x	12.39x	2.23%	223B
MERCK & CO., INC.	10.03x	3.26x	7.03x	4.12%	197B
AMGEN INC.	21.5x	5.7x	11.06x	3.31%	156B
Average	20.40x	5.63x	12.89x	3.02%	280.25B
Weighted average by Cap.	23.23x	6.78x	15.52x	2.65%